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MicroRNAs (miRNAs) have emerged as biomarkers of
metabolic status, etiological factors in complex dis-
ease, and promising drug targets. Recent reports
suggest that miRNAs are critical regulators of path-
ways underlying the pathophysiology of type 2 diabe-
tes. In this study, we demonstrate by deep sequencing
and real-time quantitative PCR that hepatic levels of
Foxa2 mRNA and miR-29 are elevated in a mouse
model of diet-induced insulin resistance. We also show
that Foxa2 and miR-29 are significantly upregulated in
the livers of Zucker diabetic fatty (fa/fa) rats and that
the levels of both returned to normal upon treatment
with the insulin-sensitizing agent pioglitazone. We
present evidence that miR-29 expression in human
hepatoma cells is controlled in part by FOXA2, which
is known to play a critical role in hepatic energy ho-
meostasis. Moreover, we demonstrate that miR-29
fine-tunes FOXA2-mediated activation of key lipid me-
tabolism genes, including PPARGC1A, HMGCS2, and
ABHD5. These results suggest that miR-29 is an impor-
tant regulatory factor in normal metabolism and may rep-
resent a novel therapeutic target in type 2 diabetes and
related metabolic syndromes.
Type 2 diabetes is characterized in part by resistance to
insulin action in the liver and other metabolic tissues (1).
MicroRNAs (miRNAs) are widely recognized as important
regulators of a diverse array of biological processes (2),
including metabolism (3). Recently, miRNAs have also
emerged as stable plasma biomarkers of physiologic and
metabolic status (4,5), etiological factors in complex disease
(6), and promising therapeutic targets (7,8). miRNA-
mediated gene regulation occurs principally at the post-
transcriptional level and has been the subject of intense
research over the past decade. Several miRNAs have been
implicated in the pathobiology of a variety of metabolic
disorders, including type 2 diabetes (9), cardiovascular
disease (10), and obesity (11). Recently, we reported that
miR-27b is a posttranscriptional regulatory hub in liver
lipid metabolism and is altered in dyslipidemia (12).
Another group of studies demonstrated that miR-33
modulates lipoprotein metabolism in mice (13–17) and
nonhuman primates (18), as well as insulin signaling in
cultured human hepatocytes (19). And, most recently, both
miR-103/107 and miR-802 (20) were shown to regulate
insulin sensitivity and glucose tolerance in mice (20,21).
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These findings strongly support the notion that miRNAs
are critical players in pathways that underlie metabolic
disease etiology, thus raising the possibility that miRNA-
based therapy could be relevant for type 2 diabetes and
related metabolic syndromes.
miR-29 has been demonstrated to be an important
regulator of numerous biological processes, including
neuronal maturation (22), fibrosis (23), hematopoiesis
(24), replicative senescence (25), and immune response
(26). Our recent in silico work identified miR-29 as the
strongest candidate miRNA regulatory hub in the type 2
diabetes gene network (27). Other groups have shown
that miR-29 is highly responsive to glucose and may
regulate b-cell proliferation and insulin secretion (28,29).
We sought to investigate miR-29 in the liver, which is
a metabolic tissue of critical relevance to type 2 diabetes
etiology.
In this study, we demonstrate that 1) hepatic miR-29
and Foxa2 mRNA are significantly upregulated in two dif-
ferent animal models of insulin resistance, 2) the insulin-
sensitizing drug pioglitazone corrects hepatic miR-29 and
Foxa2 levels in the Zucker diabetic fatty (ZDF) rat model
of diabetes, 3) miR-29 levels in hepatocytes are controlled
in part by the insulin-regulated transcription factor (TF)
FOXA2, and 4) miR-29 fine-tunes FOXA2-mediated regu-
lation of key lipid metabolism genes. Taken together, our
findings implicate miR-29 as an important regulatory fac-
tor for lipid homeostasis and motivate future studies to
investigate the utility of miR-29 as a tissue biomarker of
type 2 diabetes drug efficacy, as well as a potential ther-
apeutic target in metabolic syndromes.
RESEARCH DESIGN AND METHODS
Animal Studies
Female C57BL/6J mice were from a University of North
Carolina (UNC) at Chapel Hill colony and started at 4
weeks of age on high-fat diet (HFD) (D01060502, 45%
kcal from fat) or matched low-fat diet (LFD) (D01060501,
10% kcal from fat) (Research Diets, New Brunswick, NJ).
Livers were isolated after 16 weeks of diet and RNA was
isolated using the Norgen Total RNA Purification Kit
(Thorold, Ontario, Canada). Male ZDF rats (Charles Rivers
Laboratories) were acclimated for 2 weeks and had access
to a standard chow diet (LabDiet, St. Louis, MO). Four
weeks of pioglitazone treatment (30 mg/kg/day) was started
at 8 weeks of age. Blood was collected once a week during
treatment to measure glucose levels. Livers were isolated at
12 weeks of age, and RNA was isolated using TRIzol.
Cell Culture
Huh7 cells (human hepatoma) were obtained from
Dr. Stanley Lemon’s laboratory at UNC at Chapel Hill.
Huh7 cells were maintained in 5 mmol/L glucose Dulbecco’s
modified Eagle’s medium (Sigma-Aldrich, St. Louis, MO)
supplemented with 10% FBS, 2 mmol/L L-glutamine,
1 mmol/L Na-pyruvate, and 13 NEAA (Invitrogen, Grand
Island, NY), in 100 mm of collagen 1–coated cell culture
dishes (Becton Dickinson, Bedford, MA). For transfections,
cells were split into 6-well collagen 1–coated plates (Becton
Dickinson) to approximately 70–80% confluency, and allowed
24 h to adhere. All cells were cultured in a humidified
incubator at 37°C and 5% CO2.
Transfection Studies
Huh7 cells were plated on collagen 1–coated 6-well plates
(Becton Dickinson) 1 day before transfection. At ;70–80%
confluency, the cells were transfected with either 10 nmol/L
miRIDIAN hsa-miR-29a mimic (Thermo Scientific, Waltham,
MA), 10 nmol/L mmu-miR-29a-3p LNA inhibitor (Exiqon,
Woburn, MA), or 100 nmol/L ON-TARGETplus human
siRNA against FOXA2 (Thermo Scientific) using either
DharmaFECT 4 (Thermo Scientific) or Lipofectamine 2000
(Life Technologies, Grand Island, NY) transfection reagent.
A human FOXA2 open reading frame (ORF) expression
vector containing FOXA2 transcript variant 1 in the
pCMV6-XL5 plasmid (OriGene, Rockville, MD) was trans-
fected (1 mg) using DharmaFECT Duo transfection reagent
(Thermo Scientific). Forty-eight hours after transfection,
total RNA was isolated from the cells using the Total
RNA Purification Kit from Norgen.
Small RNA Sequencing Analysis
Total RNA was extracted from mouse liver tissue using
the Norgen Total RNA Purification Kit. RNA quality was
assessed by Agilent 2100 Bioanalyzer, and only very high-
quality samples with a RNA Integrity Number (RIN) above
8.0 were considered further. Small RNA libraries (n = 2 for
each of HFD-fed and LFD-fed mice) were generated using
the Illumina TruSeq Small RNA library preparation kit.
These libraries were then sequenced on the Illumina
HiSeq 2000 platform (50 bp reads). miRNA and isomiR
identification and quantitation were performed as de-
scribed previously (27).
Gene Expression (RNA) Analysis
Total RNA was isolated from cultured Huh7 cells or mouse
liver tissue using the Total RNA Purification Kit and sub-
jected to DNase treatment using the TURBO DNA-free Kit
(Applied Biosystems, Grand Island, NY). Complementary
DNA was synthesized using either the TaqMan MicroRNA
Reverse Transcription Kit (Applied Biosystems) or the
High-Capacity RNA-to-cDNA Kit (Applied Biosystems),
according to the manufacturer’s instructions. Real-time
PCR amplification was performed using TaqMan miRNA or
gene expression assays in TaqMan Universal PCR Master
Mix (miRNA qPCR) or TaqMan Gene Expression Master
Mix (gene expression qPCR) on a Bio-Rad CFX96 Touch
Real-Time PCR Detection System (Bio-Rad Laboratories,
Richmond, CA). Reactions were performed in triplicate using
either U6 (miRNA expression) or RPS9 (gene expression) as
the internal control. miRNA and mRNA levels were expressed
as relative quantitative values (RQVs). All TaqMan assays
used in this study were purchased from Applied Biosystems
and include miR-29a (4427975, 002112), miR-29b (4427975,
000412), miR-29c (444087, 000587), miR-15a (4427975,
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000389), U6 (4427975–001973), RPS9 (human—4331182,
Hs02339424_g1; mouse—4331182, Mm00850060_s1),
ABHD5 (4331182, Hs01104373_m1), HMGCS2 (4331182,
Hs00985427_m1), G6PC (human—4331182, Hs00609178_m1;
mouse—4331182, Mm00839363_m1), PPARGC1A (4331182,




Protein was isolated 48 to 72 h after transfection. RIPA
Buffer (Sigma-Aldrich), supplemented with complete pro-
tease inhibitor (Roche, Indianapolis, IN), phosphatase
inhibitor (Thermo Scientific), 100 mmol/L PMSF in 100%
isopropanol, 0.1% b-mercaptoethanol (VWR Interna-
tional, Radnor, PA), and 1 mol/L DTT (Fisher Scientific,
Pittsburgh, PA), was used to passively lyse adhered cells.
The lysate was collected and flash frozen before clarification
by centrifugation. Protein concentration was calculated us-
ing the Pierce Microplate BCA Protein Assay Kit—Reducing
Agent Compatible (Thermo Scientific) and run on an Any
kDMini-PROTEAN TGX Precast Gel (Bio-Rad). Transfer was
conducted using Bio-Rad Midi Transfer Packs on the Bio-
Rad Trans-Blot Turbo Blotting System. The membranes
were blocked in 5% nonfat dry milk (Sigma-Aldrich) in
TBST and probed with 1:800 anti-ABHD5 antibody (Abnova,
Cat. # H00051099-M01, Taiwan) in 4% BSA (Applied Bio-
systems, Cat. # AM2616) in TBST. Goat anti-rabbit sec-
ondary antibody (Abcam, Cat. # ab131366) was diluted
1:3,000 in 1% milk/TBST. b-Actin peroxidase (Sigma-
Aldrich Cat. # A3854) or GAPDH (Cell Signaling Technology;
Danvers, MA; Cat. # 8884s) diluted 1:40,000 in 1% milk/
TBST were used as control subjects. Signal was detected
using the Amersham ECL Prime Western Blotting Detection
Reagent (GE Healthcare Life Sciences, Piscataway, NJ) fol-
lowing manufacturer instructions, and was exposed using
the LI-COR C-DiGit Blot Scanner (LI-COR Biosciences, Lin-
coln, NE). Signal intensity was determined by densitometry
using LI-COR Biosciences Image Studio Software.
Reporter Gene (Luciferase) Assays
Human embryonic kidney 293T (HEK293T) cells were
plated at 1 3 105 cells/mL for 24 h prior to transient
transfection using DharmaFECT 4 and 500 ng/mL MT01
Firefly/Renilla luciferase reporter with the entire 39 UTR
of HMGCS2 cloned immediately downstream of Firefly
luciferase (GeneCopoeia). Cells were dual transfected
with 10 nmol/L of miR-29a mimic for 48 h prior to
cell lysis and dual luciferase assays (GeneCopoeia). Site-
directed mutagenesis was completed using QuikChange
II XL kits (Stratagene) and the following primers:
Reverse 59-agccgttgcaccgtcaggcacaggg-39 and Forward
59-ccctgtgcctgacggtgcaacggct-39. A 3 base deletion was
created in the middle of the predicted “seed” target
site for miR-29 (.tgcctgacggtggtgcaacggctgatgga.).
Bioinformatics
Chromatin immunoprecipitation sequencing (ChIP-seq)
data for Foxa2 in mouse liver and islet were published
previously (30). Chromatin occupancy sites based on these
ChIP-seq data were obtained directly from the lead author
of the study (Brad Hoffman, University of British Colum-
bia). Candidate Foxa2 target genes in mouse liver and islet
were assembled by cross-referencing the chromosomal
Figure 1—Hepatic miR-29 levels are upregulated in diet-induced
insulin resistance in mice. A: Fasting blood glucose levels of
C57BL/6J female mice on HFD for 16 weeks (n = 3) and matched
LFD for 16 weeks (n = 3) are shown. B: miRNA expression levels
(RPMM, reads per million mapped reads) based on deep sequenc-
ing analysis of small RNAs from the livers of HFD-fed (n = 2) and
LFD-fed (n = 2) C57BL/6J female mice are shown. Each circle rep-
resents a miRNA that is expressed at RPMM >100 in at least one
murine liver sample. Dashed blue lines represent 1.5-fold difference
in expression between HFD-fed and LFD-fed mice. C: Relative lev-
els (based on sequencing) of miR-29a, miR-29b, and miR-29c in the
livers of HFD-fed (n = 2) and LFD-fed (n = 2) C57BL/6J female mice
are shown. D: Relative levels (based on RT-qPCR) of miR-29a, miR-
29b, and miR-29c in the livers of HFD-fed (n = 3) and LFD-fed (n = 3)
C57BL/6J female mice are shown. P values were calculated
according to the one-tailed unpaired Student t test. a.u., arbitrary
unit. *P < 0.05; **P < 0.01; ***P < 0.001.
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locations of Foxa2 occupancy sites with gene promoter
regions (defined as windows 5 kb upstream of tran-
scription start sites as annotated in the RefSeq data-
base). The miR-29ab promoter region was identified as
recently described (31). Target site prediction for miR-
29 was performed with TargetScan 6.2 (downloaded
from http://www.targetscan.org). Statistical enrichment
of predicted miR-29 target sites among Foxa2 target genes
in the mouse liver and islet was assessed according to our
recently published method, mirHub (27), using the “non-
network” mode and requiring a predicted target site to be
conserved among at least three mammalian species includ-
ing mouse.
RESULTS
Hepatic miR-29 Is Upregulated in Animal Models of
Insulin Resistance and Is Corrected by Treatment With
the Insulin-Sensitizing Drug Pioglitazone
To determine if hepatic miR-29 levels are altered in the
insulin-resistant state, we investigated two different ani-
mal models of metabolic dysfunction. First, we studied
female C57BL/6J mice placed on a 16-week HFD (45%
kcal from fat), which resulted in significantly elevated
(;1.8-fold, P , 0.001) fasting blood glucose levels rela-
tive to age-, sex-, and strain-matched mice on LFD (10%
kcal from fat) (Fig. 1A). We performed deep sequencing
of liver small RNAs and found that miR-29b (;1.8-fold,
P , 0.05) and miR-29c (;1.9-fold, P , 0.001) were
significantly elevated in HFD-fed mice (Fig. 1B and C,
Supplementary Table 1), matching the fold increase in
miR-802 (Fig. 1B, Supplementary Table 1), which was
previously identified as a critical mediator of obesity-
induced glucose intolerance (20). To validate this find-
ing, we performed real-time quantitative PCR (RT-qPCR)
and confirmed that hepatic levels of miR-29 were signif-
icantly increased in HFD-fed mice (Fig. 1D).
Next, we examined the ZDF fa/fa rat model, which
closely mimics human adult-onset diabetes (32). We
showed that, as expected, fasting blood glucose levels
were significantly elevated (;2.5-fold, P , 0.005) in 12-
week-old male obese fa/fa rats compared with age- and
sex-matched lean healthy littermates (Fig. 2A). We then
demonstrated by RT-qPCR that hepatic miR-29a and miR-
29c levels were significantly (P , 0.05) higher for the fa/fa
rats compared with the lean littermate control subjects
(Fig. 2B). Strikingly, we also observed that treatment
with the insulin-sensitizing drug pioglitazone for 4 weeks,
which markedly improved glycemia (Fig. 2A), reduced he-
patic miR-29 expression to levels comparable to those of
the lean control subjects (Fig. 2B).
Hepatic miR-29 Expression Is Controlled in Part by the
Insulin-Regulated TF FOXA2
To investigate the molecular mechanism(s) that mediates
the upregulation of miR-29 in insulin resistance, we
sought to identify hepatic TFs regulated by insulin sig-
naling that could be involved in the control of miR-29
expression. First, we identified the transcription start sites
(TSS) of miR-29a/b-1 (chromosome 7) and miR-29b-2/c
(chromosome 1) in human hepatoma cells (HepG2) by
analyzing chromatin data from ENCODE, using our pre-
viously described bioinformatic pipeline (31). This strategy
revealed that the most proximal active TSS for miR-29a/b-1
is ;36.5 kb upstream of the mature miR-29a sequence; for
miR-29b-2/c, it is ;20 kb upstream of the mature miR-
29c sequence. We scanned these regions for areas of open
chromatin and TF occupancy in HepG2 cells, as deter-
mined by ENCODE, and found .10 binding sites for
FOXA2 at the miR-29a/b-1 locus and 4 binding sites at
the miR-29b-2/c locus (Fig. 3A). FOXA2 is negatively regu-
lated by insulin (33,34) and opposes insulin action (35) by
promoting hepatic lipid catabolism and fatty acid oxidation
(36). To further support the finding in HepG2 cells, we
mined a recently published TF ChIP-seq data set from adult
mouse liver (30) and detected Foxa2 chromatin occupancy
at the mouse miR-29 promoter regions (data not shown).
We next performed RT-qPCR and observed that
hepatic Foxa2 mRNA levels were increased in both HFD-
fed mice (Fig. 3B) and diabetic fa/fa rats (P , 0.05)
Figure 2—Hepatic miR-29 levels are elevated in a rat model of diabetes and corrected by treatment with the insulin-sensitizing drug
pioglitazone (PIO). Fasting blood glucose levels (A) and relative hepatic levels (based on RT-qPCR) of miR-29a, miR-29b, and miR-29c (B) in
12-week-old healthy male rats (n = 8), ZDF fa/fa male littermates (n = 11), and pioglitazone-treated (4 weeks) ZDF fa/fa male rats (n = 6) are
shown. P values were calculated according to the one-tailed unpaired Student t test. a.u., arbitrary unit. *P < 0.05; **P < 0.01.
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(Fig. 3C). Moreover, as with miR-29 (Fig. 3D), hepatic
Foxa2 expression in the fa/fa rats returned to that of the
lean control subjects upon treatment with pioglitazone (Fig.
3C). To more directly evaluate the potential for FOXA2
to regulate hepatic miR-29 levels, we performed small
interfering RNA (siRNA)–mediated knockdown of
FOXA2 in Huh7 cells. After 48 h of siRNA treatment,
FOXA2 mRNA was significantly reduced (P , 10212)
(Fig. 3D). Under these conditions, we observed an al-
most twofold downregulation of miR-29a (P , 0.001),
miR-29b (P , 0.05), and miR-29c (P , 0.01) (Fig. 3D).
We also transiently transfected Huh7 cells with
a FOXA2 expression vector (1 mg), which led to an
;172-fold upregulation in FOXA2 mRNA levels (P ,
0.05) and a concomitant more than twofold increase
in miR-29a (P , 0.05), miR-29b (P = 0.06), and miR-
29c (P , 0.05). Collectively, these data suggest that the
insulin-regulated FOXA2 is a transcriptional activator
of miR-29.
miR-29 Fine-tunes FOXA2-Mediated Regulation of Key
Hepatic Lipid Metabolism Genes
Recent studies of gene regulatory networks indicate that
coordinated regulation by TFs and miRNAs confers robust-
ness against environmental fluctuation (37). We assessed
the extent to which miR-29 is predicted to regulate Foxa2
gene targets in the liver. First, we assembled a list of high-
confidence hepatic target genes for Foxa2 from a published
ChIP-seq study in mouse liver (RESEARCHDESIGN ANDMETHODS).
We then determined, using our previously published
method mirHub (27), that the Foxa2 mouse liver target
gene set was significantly enriched for predicted miR-29
target sites (Fig. 4A). Notably, we did not observe this en-
richment among Foxa2 target genes in the mouse pancre-
atic islet, in which the Foxa2 regulatory network is rewired
relative to the liver (30) (Fig. 4A). To evaluate further the
predicted FOXA2–miR-29 feed-forward circuit, we experi-
mentally tested three specific instances of the circuit with
the genes HMGCS2, ABHD5, and PPARGC1A, which encode
proteins that activate the enzymatic breakdown of fat in the
liver (38,39). The mRNA levels of all three genes in Huh7
cells were significantly (P , 0.01) increased by the miR-29a
locked nucleic acid (LNA) inhibitor and significantly (P ,
0.05) reduced by the miR-29a mimic (Fig. 4B). Consistent
with this observation, the protein levels of ABHD5 were
also significantly (P , 0.05) upregulated by the miR-29a
LNA inhibitor after 48 h (Fig. 4C). Also, to determine if
miR-29 regulation of HMGCS2 is mediated through the 39
UTR, we performed a reporter gene assay (RESEARCH DESIGN
AND METHODS). Overexpression of the miR-29a mimic (100
nmol/L) in HEK293T cells significantly reduced (P , 0.01,
;65% loss) relative Firefly luciferase activity when the
HMGCS2 39 UTR was inserted downstream of the Firefly
reporter gene (Fig. 4D). Moreover, targeted deletion (3 bp)
of the predicted miR-29 target site in the HMGCS2 39 UTR
substantially mitigated the repressive effect of miR-29 on
Firefly activity (Fig. 4D). Finally, siRNA-mediated knock-
down of FOXA2 led to a significant (P , 0.01) decrease
in the expression of HMGCS2, ABHD5, and PPARGC1A
(Fig. 4E). The latter observation suggests that FOXA2 is
Figure 3—FOXA2 regulates miR-29 expression. A: FOXA2 occu-
pancy in HepG2 at the miR-29ab and miR-29b-2/c genomic loci
are shown (based on ENCODE ChIP-seq data). LOC646329 repre-
sents the putative primary transcript of miR-29a and miR-29b-1 on
chromosome 7 and Pri-miR-29b-2 represents the putative primary
transcript of miR-29b-2 and miR-29c on chromosome 1. B: Relative
levels of Foxa2mRNA in the livers of C57BL/6J female mice on HFD
for 16 weeks (n = 3) and matched LFD for 16 weeks (n = 3) are
shown. C: Relative levels of Foxa2 mRNA in the livers of 16-week-
old healthy male rats (n = 8), ZDF fa/fa male littermates (n = 11), and
pioglitazone-treated (PIO) (4 weeks) ZDF fa/fa male rats (n = 6) are
shown. D: Effects of FOXA2-siRNA treatment (100 nmol/L) in Huh7
cells on FOXA2 (mock, n = 14; siRNA, n = 13), miR-29a (mock, n =
12; siRNA, n = 12), and miR-29b and miR-29c (mock, n = 10; siRNA,
n = 8) expression levels are shown. E: Effects of FOXA2 open read-
ing frame (ORF) overexpression plasmid (1 mg) in Huh7 cells on
FOXA2 (mock, n = 6; plasmid, n = 5), miR-29a (mock, n = 6; plas-
mid, n = 5), miR-29b (mock, n = 5; plasmid, n = 4), and miR-29c
(mock, n = 6; plasmid, n = 5) are shown. All transfections were
conducted in triplicate and results were validated by at least two
independent experiments. P values were calculated according to
the two-tailed unpaired Student t test. a.u., arbitrary unit. *P <
0.05; **P < 0.01; ***P < 0.001.
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the primary driver of the expression levels of its target
genes, whereas miR-29 serves as a feed-forward negative
modulator (Fig. 5).
DISCUSSION
This study leveraged in vivo, in vitro, and in silico
analyses to uncover a role for miR-29 as a potentially
critical regulator of hepatic metabolic pathways. A prior
study suggested that miR-29 is significantly elevated in
the livers of the diabetic mouse model db/db (40); how-
ever, to our knowledge, this result had not been validated
in other models. We showed in this study that liver miR-
29 levels are elevated in two different animal models
of metabolic dysfunction and, notably, are returned to
normal levels upon treatment with an insulin sensitizer,
pioglitazone, in the ZDF fa/fa rat. This finding signals the
possibility that miRNAs could serve as tissue biomarkers
of drug efficacy in type 2 diabetes.
Two recent miRNA profiling studies reported that type
2 diabetes might be associated with reduced levels of
plasma miR-29 (41,42). We observe in this study that
miR-29 is elevated in the liver of animals with insulin
resistance and diabetes. The apparent inverse correlation
between plasma and liver miR-29 levels in type 2 diabetes
is intriguing. It is now widely appreciated that miRNAs
are stably present in circulation and are transported by
a variety of different types of extracellular vehicles (EVs),
including exosomes and high-density lipoproteins (43–47).
Several studies have shown that numerous cell types se-
crete miRNAs, which can then be loaded onto EVs and
delivered to recipient cells with functional integrity (48–
50). However, the mechanisms that regulate intercellular
Figure 4—miR-29 fine-tunes FOXA2-mediated regulation of key lipid metabolism genes. A: Significant enrichment of predicted miR-29
target sites among FOXA2-bound genes in mouse liver but not in mouse islet is shown. Dashed line reflects P = 0.05. B: Effects of the miR-
29a mimic (10 nmol/L) and the miR-29a LNA inhibitor (10 nmol/L) in Huh7 cells on the mRNA levels of FOXA2-bound genes HMGCS2
(mimic, n = 7; LNA, n = 7), ABHD5 (mimic, n = 8; LNA, n = 6), and PPARGC1A (mimic, n = 7; LNA, n = 7) are shown. C: Effect of the miR-29a
inhibitor (LNA, 10 nmol/L) in Huh7 cells on protein levels of ABHD5 is shown (mock, n = 3; LNA, n = 3). D: Effects of the miR-29a mimic (100
nmol/L) in HEK293T cells on the relative activity of Firefly reporter constructs containing either wild-type or mutated HMGCS2 39 UTR are
shown. Firefly activity was normalized to Renilla activity. E: Effects of FOXA2-siRNA treatment (100 nmol/L) in Huh7 cells on mRNA levels
of HMGCS2 (mock, n = 10; siRNA, n = 9), ABHD5 (mock, n = 10; siRNA, n = 10), and PPARGC1A (mock, n = 8; siRNA, n = 4) are shown.
P values were calculated according to the two-tailed unpaired Student t test. a.u., arbitrary unit. *P < 0.05; **P < 0.01; ***P < 0.001.
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miRNA transfer remain poorly characterized and represent
a nascent but promising topic of research. Progress in this
area will be critical for understanding why liver miR-29 is
elevated but plasma miR-29 is reduced in type 2 diabetes.
miR-29 is highly expressed in numerous metabolic tissues,
including the pancreatic islet (27,51), and the relative con-
tribution of each of these tissues to circulating miR-29
remains to be determined and merits further investigation.
We also demonstrated in this study that hepatic miR-
29 expression is likely controlled at least in part by the
insulin-regulated TF, FOXA2, which contains .10 ChIP-
seq–derived binding sites in human hepatoma cells at the
miR-29ab genomic locus on chromosome 7 and four bind-
ing sites at the miR-29bc genomic locus on chromosome
1. The evaluation of the combinatorial effect of these
binding sites on miR-29 transcription is not trivial; how-
ever, it certainly warrants further investigation to more
definitively establish direct FOXA2-mediated regulation of
miR-29. Moreover, future studies in vivo should establish
the extent to which FOXA2 controls miR-29 during he-
patic insulin resistance.
Finally, we showed that miR-29 serves as a dampener
of FOXA2-mediated activation of key lipid metabolism
genes. For example, FOXA2 transcriptionally activates
HMGCS2, which in turn is directly repressed by miR-29. It
has been postulated that such TF:miRNA regulatory cir-
cuits, termed incoherent feed-forward loops, are likely im-
portant for noise buffering of gene expression (37,52,53).
Further detailed studies in vivo may help elucidate the
physiological importance of the FOXA2:miR-29 regulatory
circuit in lipid homeostasis.
Overall, this study strongly suggests that miR-29
merits further investigation as a candidate biomarker of
metabolic status and drug efficacy, an etiological factor in
type 2 diabetes, and a potentially important therapeutic
target for a range of metabolic disorders.
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